Bal Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bal Pharma Ltd. on BSE

Load latest

Bal Pharma Ltd.

04 Jul 2024

89.64

6.84%

Company Update

BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We are submitting the confirmation of compliance with Regulation 74(5) SEBI(DP) Regulations, for the quarter ended 30.06.2024.

pdf

Bal Pharma Ltd.

28 Jun 2024

89.64

6.84%

Company Update

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

We would like to inform the exchanges that Dr.C.V Srinivas ( DIN# 04495304) Independent Director of the Company has completed his tenure of five years as Independent Director of the Company and he ceases to be on the Board of the Company w.e.f 28.06.2024.

pdf

Bal Pharma Ltd.

25 Jun 2024

89.64

6.84%

SAST

BAL PHARMA LTD. - 524824 - Closure of Trading Window

BSE India

Trading Window of the Company on designated persons and their immediate relatives will be closed from 1st July 2024 until 48 hours of declaration of the Un Audited financial results for the quarter ended 30.06.2024.

pdf

Bal Pharma Ltd.

03 Jun 2024

89.64

6.84%

Corp. Note

BAL PHARMA LTD. - 524824 - Disclosure under Regulation 30A of LODR

BSE India

Disclosure as per Regulation 31 A of SEBI (LODR) Regulations- Intimation reg receipt of applications from promoters for reclassification of their shareholding in the Company as Public holding.

pdf

Bal Pharma Ltd.

30 May 2024

89.64

6.84%

Company Update

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

In compliance with Regulation 47 of SEBI(LODR) Regulations, we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024.

pdf

Bal Pharma Ltd.

29 May 2024

89.64

6.84%

Corp. Action

BAL PHARMA LTD. - 524824 - Corporate Action-Board approves Dividend

BSE India

Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12%, which is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting .

pdf

Bal Pharma Ltd.

29 May 2024

89.64

6.84%

Annual Report

Annual report for Bal Pharma Ltd. for FY-2024

None

pdf

Bal Pharma Ltd.

28 May 2024

89.64

6.84%

Result

BAL PHARMA LTD. - 524824 - Audited Financial Results 31.03.2024

BSE India

Audited stand alone & Consolidated financial results for the quarter and financial year ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.

pdf

Bal Pharma Ltd.

28 May 2024

89.64

6.84%

Board Meeting

BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting

BSE India

Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25.

pdf

Bal Pharma Ltd.

27 May 2024

89.64

6.84%

Company Update

BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024.

pdf

No results found

Is Bal Pharma Ltd. worth buying?

52 Votes:

Buy 76.92%

Sell 13.46%

Hold 9.62%